<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chronic hypertension in pregnancy: Prenatal and postpartum care</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chronic hypertension in pregnancy: Prenatal and postpartum care</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chronic hypertension in pregnancy: Prenatal and postpartum care</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arun Jeyabalan, MD, MSCR</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jacob C Larkin, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1168982604"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>In pregnant patients, chronic hypertension (also called preexisting hypertension) can be defined as hypertension known to be present before conception or first recognized before 20 weeks of gestation. In patients with a previous pregnancy complicated by gestational hypertension, hypertension that persists 12 or more weeks after giving birth is also classified as chronic.</p><p>Patients with chronic hypertension are at risk for a variety of adverse maternal and fetal/neonatal outcomes  (<a class="graphic graphic_table graphicRef127248" href="/d/graphic/127248.html" rel="external">table 1</a>), some of which can be mitigated by appropriate pregnancy management.</p><p>This topic will discuss the risks and management of pregnancy complicated by chronic hypertension. Treatment of high blood pressure in pregnancy is reviewed separately. (See  <a class="medical medical_review" href="/d/html/6815.html" rel="external">"Treatment of hypertension in pregnant and postpartum patients"</a>.)</p><p class="headingAnchor" id="H4202719096"><span class="h1">DEFINITION/DIAGNOSTIC CRITERIA</span></p><p class="headingAnchor" id="H486053029"><span class="h2">Pregnancy</span><span class="headingEndMark"> — </span>Diagnostic definitions for the various hypertensive disorders associated with pregnancy are described in the table  (<a class="graphic graphic_table graphicRef127246" href="/d/graphic/127246.html" rel="external">table 2</a>) [<a href="#rid1">1,2</a>].</p><p>Blood pressure criteria for hypertension in pregnancy are [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension – Systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or both.</p><p class="bulletIndent1"><span class="glyph">●</span>Severe hypertension – Systolic blood pressure ≥160 mmHg, diastolic blood pressure ≥110 mmHg, or both. </p><p></p><p>Hypertension should be confirmed by at least two measurements (at least four hours apart except for blood pressures in the severe range, which should be repeated sooner and treated).</p><p>In pregnant patients who first present for prenatal care in the second trimester without recent prepregnancy blood pressure measurements for comparison, the diagnosis of chronic hypertension can be missed due to the normal physiologic decrease in blood pressure between 12 and 19 weeks of gestation: systolic and diastolic blood pressures are approximately 5 to 10 mmHg below baseline at this time. (See  <a class="medical medical_review" href="/d/html/443.html" rel="external">"Maternal adaptations to pregnancy: Cardiovascular and hemodynamic changes", section on 'Changes in systemic hemodynamics'</a>.)</p><p class="headingAnchor" id="H2837632957"><span class="h2">Nonpregnant individuals</span><span class="headingEndMark"> — </span>Blood pressure criteria for hypertension had been the same in pregnant and nonpregnant individuals until 2017, when the American College of Cardiology (ACC) and the American Heart Association (AHA) modified the traditional criteria for diagnosing hypertension in nonpregnant adults to better identify and modify long-term cardiovascular risk [<a href="#rid4">4</a>] (see  <a class="medical medical_review" href="/d/html/3852.html" rel="external">"Overview of hypertension in adults", section on 'Definitions'</a>). Under the new criteria, blood pressure criteria for hypertension in nonpregnant adults are [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated blood pressure – Systolic blood pressure 120 to 129 mmHg and diastolic blood pressure &lt;80 mmHg.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stage 1 hypertension – Systolic blood pressure 130 to 139 mmHg or diastolic blood pressure 80 to 89 mmHg.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stage 2 hypertension – Systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg.</p><p></p><p>These new criteria are estimated to at least double the number of reproductive-age females in the United States diagnosed with chronic hypertension [<a href="#rid4">4,6,7</a>], but the pregnancy implications remain unclear. A meta-analysis demonstrated a stepwise relationship between the ACC/AHA blood pressure categories above and the strength of the association with preeclampsia [<a href="#rid8">8</a>]. There was a progressive increase in risk ratios (RRs) from the elevated blood pressure category (RR 2.0, 95% prediction interval [PI] 0.8-4.8) to stage 1 hypertension (RR 3.0, 95% PI 1.1-8.5) to stage 2 hypertension (RR 7.9, 95% PI 1.8-35.1). However, the authors concluded that lowering the blood pressure threshold below 140/90 mmHg at &lt;20 weeks of gestation would not assist clinicians in identifying patients at heightened maternal or perinatal risk since the negative likelihood ratio was &gt;2.0.</p><p>In this topic, the term "chronic hypertension" will be used to refer to patients who meet current ACC/AHA criteria for stage 2 hypertension unless otherwise noted. Further evidence is needed to determine whether pregnancy management should differ for those with stage 1 versus stage 2 hypertension. The American College of Obstetricians and Gynecologists suggests a conservative management approach to patients with stage 1 hypertension, such as closer maternal monitoring during pregnancy [<a href="#rid2">2</a>]</p><p class="headingAnchor" id="H2113928967"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Among pregnant individuals in the United States, the prevalence of chronic hypertension was 2.3 percent in 2019 [<a href="#rid9">9</a>]. The prevalence has increased severalfold in recent decades, largely related to increasing maternal age and increasing obesity in the population. The prevalence is twofold higher in pregnant Black individuals compared with pregnant White individuals (4.3 versus 2 percent). (See  <a class="medical medical_review" href="/d/html/5370.html" rel="external">"Overweight and obesity in adults: Health consequences", section on 'Hypertension'</a> and  <a class="medical medical_review" href="/d/html/3875.html" rel="external">"Overweight, obesity, and weight reduction in hypertension"</a>.)</p><p class="headingAnchor" id="H740060980"><span class="h1">RISKS OF CHRONIC HYPERTENSION IN PREGNANCY</span><span class="headingEndMark"> — </span>Chronic hypertension and cardiovascular disease are among the leading causes of maternal and fetal/neonatal morbidity and mortality  (<a class="graphic graphic_table graphicRef127248" href="/d/graphic/127248.html" rel="external">table 1</a>) [<a href="#rid10">10,11</a>]. Superimposed preeclampsia, which develops in 13 to 40 percent of pregnant individuals with chronic hypertension, increases the risk of adverse outcomes [<a href="#rid12">12,13</a>]. (See <a class="local">'Patients with superimposed preeclampsia'</a> below.)</p><p>The frequency of adverse outcomes is difficult to cite precisely because reports do not uniformly distinguish between pregnancies complicated by superimposed preeclampsia and those with uncomplicated chronic hypertension alone. Where possible, we will review outcomes of patients with chronic hypertension alone, acknowledging that most analyses combine these outcomes with those in patients with superimposed preeclampsia.</p><p class="headingAnchor" id="H1321695020"><span class="h2">Maternal risks</span><span class="headingEndMark"> — </span>Population-based studies, as well as systematic reviews and meta-analyses, consistently demonstrate an increased risk of adverse maternal outcomes associated with chronic hypertension in pregnancy [<a href="#rid10">10,14-18</a>]. The risk increases with the severity of hypertension and presence of end-organ damage [<a href="#rid19">19-22</a>]. Although the relative risks (RR) for these complications are significantly increased, the absolute risk for serious end-organ damage (eg, heart, kidney, brain) is low in the absence of preeclampsia or uncontrolled hypertension. Obesity may be a confounder since it is associated with hypertension, diabetes, insulin resistance, chronic inflammation, and endothelial dysfunction [<a href="#rid23">23</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute kidney failure</strong> – 5.9 per 1000 deliveries (odds ratio [OR] 14.6, 95% CI 12.1-17.7) [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary edema</strong> – 1.5 per 1000 deliveries (OR 9.3, 95% CI 6.7-12.9) [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Superimposed preeclampsia</strong> – 13 to 40 percent [<a href="#rid10">10,12,13,24</a>] (RR 7.7, 95% CI 5.7-10.1) [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>In-hospital mortality</strong> – 0.4 per 1000 deliveries (OR 6.2, 95% CI 3.3-11.5) [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stroke/cerebrovascular complications</strong> – 2.7 per 1000 deliveries (OR 5.4, 95% CI 4.3-6.9) [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cesarean birth</strong> – Estimated prevalence 41.4 percent (95% CI 35.5-47.7) [<a href="#rid16">16</a>] (OR 2.7, 95% CI 2.4-3) [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Placental abruption</strong> (adjusted OR 2.3, 95% CI 1.5-3.5) [<a href="#rid18">18</a>], with the highest risk in patients with superimposed preeclampsia [<a href="#rid12">12,18,26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postpartum hemorrhage</strong> (OR 2.2, 95% CI 1.4-3.7) [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gestational diabetes</strong> – 8.1 percent (adjusted OR 1.6, 95% CI 1.3-2.1) [<a href="#rid15">15</a>], likely reflecting common risk factors, such as obesity, and similar pathogenic mechanisms, such as insulin resistance [<a href="#rid16">16,17,27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hospitalization</strong> – Mean inpatient length of stay for chronic hypertension without preeclampsia 5.4 days (standard deviation [SD] 7 days) [<a href="#rid24">24</a>] and 12.7 days (SD 9.3) for superimposed preeclampsia; odds of length of stay &gt;6 days (OR 6.7, 95% CI 6.2-7.3) [<a href="#rid10">10,27</a>].</p><p></p><p class="headingAnchor" id="H2717457467"><span class="h2">Fetal/neonatal risks</span><span class="headingEndMark"> — </span>Rates of adverse perinatal outcomes are higher among offspring of mothers with longer duration and greater severity of hypertension, presence of end-organ damage, and occurrence of superimposed preeclampsia.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Perinatal mortality</strong> – Perinatal mortality is two to four times higher in pregnancies complicated by chronic hypertension compared with pregnancies in the general obstetric population, and the increase persists after adjusting for preeclampsia and birth weight [<a href="#rid15">15,25,28,29</a>]. The increase in perinatal mortality is likely attributable to increases in indicated preterm birth and fetal growth restriction (FGR).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preterm birth, low birth weight, neonatal intensive care unit admission</strong> – In a meta-analysis comparing pregnancy outcomes of individuals with chronic hypertension with population-based data (55 studies, nearly 800,000 pregnancies), patients with chronic hypertension had a threefold increase in the pooled incidence of the following outcomes [<a href="#rid25">25</a>]: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Preterm birth &lt;37 weeks (33 and 12 percent, respectively, RR 2.7, 95% CI 1.9-3.6).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Birth weight &lt;2500 grams (22 and 8 percent, respectively, RR 2.7, 95% CI 1.9-3.8).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Newborns admitted to the neonatal intensive care unit (19 and 6 percent, respectively, RR 3.2, 95% CI 2.2-4.4).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Small for gestational age</strong> – In a prospective cohort study of pregnant patients receiving care in the United Kingdom that compared outcomes of those with chronic hypertension (n = 1417) to those without (n = 108,515), patients with chronic hypertension were twice as likely to give birth to a small for gestational age (SGA) newborn (19.2 versus 10.9 percent, adjusted OR 2.06, 95% CI 1.79-2.39) [<a href="#rid15">15</a>]. The increased risk of SGA with chronic hypertension was not confined to patients with superimposed preeclampsia; in stratified analysis of those with chronic hypertension alone, the odds of an SGA neonate remained elevated (OR 1.66, 95% CI 1.41-1.95). Other reports indicate even higher rates of SGA for patients with chronic hypertension, exceeding 30 percent [<a href="#rid30">30,31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital malformations</strong> – In both untreated and treated patients with chronic hypertension, chronic hypertension in pregnancy has also been associated with an increased risk for congenital malformations, with RR estimates for congenital cardiac malformations ranging from 1.4 to 1.5 for untreated hypertension and 1.6 to 2 for treated hypertension [<a href="#rid32">32,33</a>]. Smaller studies have suggested an increase in other anomalies, including esophageal atresia and hypospadias [<a href="#rid34">34</a>]. Further investigation is needed to understand the pathophysiology underlying these associations. We believe these findings warrant obtaining a fetal anatomic survey at 18 to 20 weeks of gestation (which is routine even in patients without chronic hypertension), but not routine fetal echocardiography, which should be ordered selectively for standard indications. (See  <a class="medical medical_review" href="/d/html/6755.html" rel="external">"Congenital heart disease: Prenatal screening, diagnosis, and management"</a>.) </p><p></p><p class="headingAnchor" id="H3847263861"><span class="h2">Long-term prognosis</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maternal</strong> – Both chronic hypertension and preeclampsia are clearly associated with increased cardiovascular risk in later life [<a href="#rid35">35-39</a>]. (See  <a class="medical medical_review" href="/d/html/3852.html" rel="external">"Overview of hypertension in adults", section on 'Complications of hypertension'</a> and  <a class="medical medical_review" href="/d/html/1468.html" rel="external">"Overview of atherosclerotic cardiovascular risk factors in females", section on 'Hypertensive disorder of pregnancy'</a> and  <a class="medical medical_review" href="/d/html/139247.html" rel="external">"Preeclampsia: Intrapartum and postpartum management and long-term prognosis", section on 'Long-term maternal risks of pregnancy-associated hypertension'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Offspring</strong> – The existing data on long-term offspring outcomes of pregnancies complicated by chronic hypertension are largely population-based and do not always account for preeclampsia, medication use, severity of disease, and gestational age at birth. With these limitations, long-term follow-up of offspring of pregnancies complicated by hypertensive disorders in the Helsinki Birth Cohort showed a modest association with self-reported cognitive decline and mental and mood disorders [<a href="#rid40">40-42</a>]. Kidney, immune, endocrine, and gastrointestinal system abnormalities in children and adolescents have also been associated with in utero exposure to hypertensive disorders in pregnancy [<a href="#rid43">43</a>].</p><p></p><p class="headingAnchor" id="H1785542698"><span class="h1">PRECONCEPTION CARE</span><span class="headingEndMark"> — </span>Ideally, patients with chronic hypertension are seen prior to conception to address the following issues, which are summarized in the table  (<a class="graphic graphic_table graphicRef127249" href="/d/graphic/127249.html" rel="external">table 3</a>), in addition to routine preconception assessments (see  <a class="medical medical_review" href="/d/html/448.html" rel="external">"The preconception office visit"</a>). Maternal-fetal medicine consultation should be considered for counseling and management both preconception and during pregnancy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Counseling</strong> – Counseling is provided about the pregnancy risks of chronic hypertension and the potential interventions to minimize these risks. Patients are informed about the anticipated course of pregnancy, need for heightened maternal and fetal surveillance, and likely need for more frequent obstetric visits and possibly hospitalization (eg, if superimposed preeclampsia develops) compared with a low-risk population. (See <a class="local">'Risks of chronic hypertension in pregnancy'</a> above and <a class="local">'Patients with superimposed preeclampsia'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Consideration of secondary causes of hypertension </strong>– While the majority of hypertensive, reproductive-age females with chronic hypertension have essential (idiopathic or primary) hypertension, consideration of secondary causes of hypertension is important (summarized in the table  (<a class="graphic graphic_table graphicRef127250" href="/d/graphic/127250.html" rel="external">table 4</a>)), if not already evaluated, since these causes can require specific testing and therapy, ideally before pregnancy. A finding suggestive of secondary hypertension is resistant hypertension, particularly in younger patients (&lt;30 years) with no family history of hypertension. (See  <a class="medical medical_review" href="/d/html/3849.html" rel="external">"Initial evaluation of adults with hypertension"</a> and  <a class="medical medical_review" href="/d/html/3862.html" rel="external">"Evaluation of secondary hypertension"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory tests</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Creatinine </p><p class="bulletIndent2"><span class="glyph">•</span>Urine protein/creatinine ratio or 24-hour urine protein </p><p></p><p class="bulletIndent1">If abnormal, detailed information on issues related to chronic kidney disease in pregnancy is available separately. (See  <a class="medical medical_review" href="/d/html/7205.html" rel="external">"Pregnancy and contraception in patients with nondialysis chronic kidney disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac evaluation</strong> – Baseline cardiac evaluation is recommended in patients with long-standing hypertension, based on age or poorly controlled hypertension for more than four years, given the increased risk of cardiac hypertrophy, dysfunction, and ischemic heart disease [<a href="#rid2">2</a>]. Because of the enhanced detection of left ventricular hypertrophy and cardiac dysfunction, we utilize transthoracic echocardiography for baseline cardiac evaluation. When echocardiography is not available, a twelve-lead electrocardiogram can be used as an alternative first-line test. (See  <a class="medical medical_review" href="/d/html/3849.html" rel="external">"Initial evaluation of adults with hypertension"</a>.)</p><p></p><p class="bulletIndent1">Issues related to pregnant patients with acquired heart disease are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/8148.html" rel="external">"Acquired heart disease and pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood pressure management</strong> – For patients who have achieved stable blood pressure control with pharmacotherapy and are considering pregnancy or attempting to conceive, the risks and benefits of continuing a stable antihypertensive drug regimen versus changing the regimen to the few drugs preferred for use in pregnant patients (<a class="drug drug_general" data-topicid="9540" href="/d/drug information/9540.html" rel="external">labetalol</a>, <a class="drug drug_general" data-topicid="9700" href="/d/drug information/9700.html" rel="external">nifedipine</a>, <a class="drug drug_general" data-topicid="9635" href="/d/drug information/9635.html" rel="external">methyldopa</a>) must be considered. For patients who have not achieved stable blood pressure control, blood pressure should be optimized. We suggest shared decision-making involving the obstetrician/maternal-fetal medicine specialist, primary care provider, and patient. Drug choice and target blood pressure are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6815.html" rel="external">"Treatment of hypertension in pregnant and postpartum patients", section on 'Preconception management of chronic hypertension'</a>.)</p><p></p><p class="bulletIndent1">However, <strong>angiotensin converting enzyme inhibitors and angiotensin receptor blockers</strong> <strong>should be discontinued</strong> before pregnancy since they have been associated with congenital malformations, including renal dysgenesis and calvarial hypoplasia, as well as fetal growth restriction and oligohydramnios [<a href="#rid44">44-46</a>]. (See  <a class="medical medical_review" href="/d/html/4789.html" rel="external">"Adverse effects of angiotensin converting enzyme inhibitors and receptor blockers in pregnancy", section on 'Clinical approach to use of RAAS inhibitors in females of childbearing potential'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Modifiable risk factors</strong> – Weight loss in patients who are overweight or obese, smoking cessation in smokers, increased exercise for sedentary individuals, and dietary changes (eg, sodium restriction, Dietary Approaches to Stop Hypertension [DASH] diet) when appropriate are encouraged as nonpharmacologic means of reducing blood pressure and potentially improving pregnancy outcome and overall health. (See  <a class="medical medical_review" href="/d/html/3852.html" rel="external">"Overview of hypertension in adults", section on 'Nonpharmacologic therapy'</a> and  <a class="medical medical_review" href="/d/html/412.html" rel="external">"Exercise during pregnancy and the postpartum period"</a> and  <a class="medical medical_review" href="/d/html/433.html" rel="external">"Obesity in pregnancy: Complications and maternal management"</a> and  <a class="medical medical_review" href="/d/html/115306.html" rel="external">"Tobacco and nicotine use in pregnancy: Cessation strategies and treatment options"</a>.)</p><p></p><p class="headingAnchor" id="H2819358595"><span class="h1">PRENATAL CARE AND DELIVERY</span></p><p class="headingAnchor" id="H1518887993"><span class="h2">Patients with chronic hypertension</span><span class="headingEndMark"> — </span>The<strong> </strong>following discussion applies to the prenatal care and delivery of patients with chronic hypertension without superimposed preeclampsia. Monitoring for development of superimposed preeclampsia is a key component of the prenatal care of these patients. If it develops, pregnancy management needs to be modified because preeclampsia is a progressive and potentially life-threatening disease. (See <a class="local">'Patients with superimposed preeclampsia'</a> below.)</p><p class="headingAnchor" id="H3515319351"><span class="h3">Baseline clinical evaluation, laboratory testing, and preeclampsia prophylaxis</span></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical evaluation should include baseline blood pressure and heart rate and a general physical examination, including cardiopulmonary auscultation and evaluation for any signs of cardiac dysfunction (ie, cyanosis, hepatomegaly, jugular venous distention, pulmonary edema). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In addition to routine prenatal laboratory testing, the following laboratory tests are recommended, if not obtained within the six months prior to conception:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Creatinine</p><p class="bulletIndent2"><span class="glyph">•</span>Urine protein/creatinine ratio or 24-hour urine protein</p><p></p><p class="bulletIndent1">We also obtain liver transaminases (aspartate aminotransferase and alanine aminotransferase) and a platelet count as a baseline, as this information is useful if the patient develops signs/symptoms of preeclampsia later in pregnancy. We obtain electrolytes in patients with kidney dysfunction. We test for overt diabetes in patients with obesity. (See  <a class="medical medical_review" href="/d/html/6797.html" rel="external">"Gestational diabetes mellitus: Screening, diagnosis, and prevention", section on 'Screening for overt diabetes in early pregnancy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If not assessed within one year prior to conception, transthoracic echocardiography or a twelve-lead electrocardiogram is suggested for patients with long-standing hypertension, based on age or poorly controlled hypertension for more than four years [<a href="#rid2">2</a>]. Cardiac dysfunction increases morbidity in pregnancy and peripartum, given the increase in cardiac output and cardiac stress. (See <a class="local">'Preconception care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Accurate gestational dating is particularly important given the increased risks for growth restriction and indicated preterm birth in patients with chronic hypertension. Whether to perform a dating ultrasound examination in the first trimester or wait until the time of the 18- to 20-week fetal anatomic survey depends on the clinician's confidence in the menstrual dates. (See  <a class="medical medical_review" href="/d/html/5391.html" rel="external">"Prenatal assessment of gestational age, date of delivery, and fetal weight"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> is recommended after 12 weeks of gestation for preeclampsia prophylaxis as these patients are at high risk of developing the disease [<a href="#rid47">47</a>]. Based on the existing evidence and dose availability in the United States, we use 81 mg daily. Some have advocated higher doses (100 to 150 mg daily) based on a meta-analysis of eight trials [<a href="#rid48">48</a>]; however, there was significant heterogeneity and none of the trials directly compared the higher doses with 81 mg.</p><p></p><p class="bulletIndent1">Although the efficacy of low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> has been established in meta-analyses of randomized trials of patients at high-risk of developing preeclampsia (see  <a class="medical medical_review" href="/d/html/6817.html" rel="external">"Preeclampsia: Prevention", section on 'Evidence of efficacy'</a>), a meta-analysis limited to patients with chronic hypertension did not show statistically significant reductions in superimposed preeclampsia (24.6 versus 30.0 percent; OR 0.74, 95% CI 0.47-1.16; four trials, 992 patients), SGA births, or perinatal mortality [<a href="#rid49">49</a>]. There was low certainty of this finding given the high risk of bias in the trials, inconsistency (aspirin was effective in two of the four trials), and high heterogeneity. Preterm birth was reduced (OR 0.63, 95% CI 0.45-0.89) based on moderate quality evidence. We use aspirin prophylaxis in patients with chronic hypertension given that evidence for lack of preeclampsia benefit and other outcomes is low quality and evidence for reduction of preterm birth is moderate quality.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Initiation and discontinuation of antihypertensive therapy, as appropriate, which is discussed below. (See <a class="local">'Blood pressure management'</a> below.)</p><p></p><p class="headingAnchor" id="H2950878969"><span class="h3">Diet and gestational weight gain</span><span class="headingEndMark"> — </span>Patients should be encouraged to meet gestational weight gain targets that are appropriate for their body mass index  (<a class="graphic graphic_table graphicRef75820" href="/d/graphic/75820.html" rel="external">table 5</a>). In particular, excessive gestational weight gain should be avoided because increased adiposity is strongly associated with higher blood pressure. Excessive gestational weight gain can also lead to significant postpartum weight retention. (See  <a class="medical medical_review" href="/d/html/441.html" rel="external">"Gestational weight gain", section on 'Recommendations for gestational weight gain'</a>.)</p><p>There is minimal information on the effects of initiating a low salt or Dietary Approaches to Stop Hypertension (DASH) diet before pregnancy or continuing it throughout pregnancy [<a href="#rid50">50-53</a>]. However, these are healthy dietary approaches and would be reasonable to continue during pregnancy. (See  <a class="medical medical_review" href="/d/html/6815.html" rel="external">"Treatment of hypertension in pregnant and postpartum patients", section on 'Diet'</a>.)</p><p class="headingAnchor" id="H2629733689"><span class="h3">Ongoing maternal monitoring</span><span class="headingEndMark"> — </span>Obstetric provider visits should include measurement of blood pressure and assessment for potential symptoms of superimposed preeclampsia. More frequent visits than standard schedules (which may be at two- to four-week intervals) for blood pressure monitoring may be needed in the setting of poorly controlled blood pressure or if ongoing medication titration is needed. </p><p class="bulletIndent1"><span class="glyph">●</span>Blood pressures should be measured with the appropriate sized cuff, proper positioning, and after a five-minute rest period; ideally, a blood pressure cuff that has been validated in pregnancy should be used [<a href="#rid54">54,55</a>]. Home blood pressure monitoring is generally reliable, useful for complementing office visits, and may reduce office visits and the need for hospitalization [<a href="#rid56">56,57</a>]. We use this approach in our practice. In a meta-analysis, systolic blood pressure values measured at home were lower than office values by 4 mmHg (95% CI -6 to -3) and diastolic measurements were lower by 3 mmHg (95% CI -4 to -2) [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/d/html/6815.html" rel="external">"Treatment of hypertension in pregnant and postpartum patients", section on 'Technique for accurate measurement of blood pressure'</a>.)</p><p></p><p class="bulletIndent1">While increasing blood pressure, possibly in the late second trimester and more commonly in the third trimester, could indicate the anticipated physiologic rise in blood pressure in the second half of pregnancy, superimposed preeclampsia must be excluded, based on gestational age at onset, symptoms and laboratory studies, risk factors, and course over time. We have a low threshold for in-hospital evaluation if superimposed preeclampsia is suspected. (See <a class="local">'Clinical presentation and evaluation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient education on the symptoms and signs of preeclampsia and clear instructions about when to contact providers are essential. Symptoms of persistent and/or severe headache, visual changes (scotomata, photophobia, blurred vision, or temporary blindness [rare]), right upper quadrant or epigastric pain, new onset of nausea or vomiting in the third trimester, new onset of shortness of breath, altered mental status, or vaginal bleeding warrant additional investigation. (See  <a class="medical medical_review" href="/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis", section on 'Clinical presentation'</a>.)</p><p></p><p class="headingAnchor" id="H590441026"><span class="h3">Blood pressure management</span><span class="headingEndMark"> — </span>Recommendations for management of severe hypertension and nonsevere chronic hypertension in pregnancy are reviewed below, along with supporting evidence.</p><p>Although the American College of Cardiology and the American Heart Association have published recommendations for management of chronic hypertension in nonpregnant individuals, these guidelines are not fully generalizable to pregnant individuals due to fetal safety concerns and the physiologic changes of pregnancy and because the long-term goals of adult hypertension treatment over the course of a lifetime are different from those of the short-term time frame of pregnancy. </p><p class="headingAnchor" id="H3326844926"><span class="h4">Severe hypertension</span><span class="headingEndMark"> — </span>Regardless of etiology (chronic hypertension, gestational hypertension, preeclampsia), there is consensus among medical organizations that severe maternal hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥110 mmHg) should be pharmacologically treated in a timely manner to reduce the risk for maternal cerebrovascular, cardiac, and renal events, as well as death [<a href="#rid2">2,59,60</a>]. Evidence for this recommendation is extrapolated from studies on the management of preeclampsia and on management of severe hypertension in nonpregnant adults, with few studies conducted exclusively in pregnant patients with chronic hypertension [<a href="#rid4">4,5,61</a>]. (See  <a class="medical medical_review" href="/d/html/6791.html" rel="external">"Preeclampsia with severe features: Delaying delivery in pregnancies remote from term", section on 'Morbidity and mortality'</a> and  <a class="medical medical_review" href="/d/html/3830.html" rel="external">"Management of severe asymptomatic hypertension (hypertensive urgencies) in adults"</a> and  <a class="medical medical_review" href="/d/html/3837.html" rel="external">"Evaluation and treatment of hypertensive emergencies in adults"</a>.)</p><p>The general principle is to gradually lower blood pressure below the severely elevated range and into the mildly elevated range, thereby avoiding an acute reduction in uterine artery blood flow. The optimal blood pressure target for maintenance therapy after this initial reduction is less clear. We believe a target blood pressure range of 120 to 139/80 to 89 mmHg is reasonable. (See  <a class="medical medical_review" href="/d/html/6815.html" rel="external">"Treatment of hypertension in pregnant and postpartum patients", section on 'Oral maintenance therapy'</a>.)</p><p>The choice of medication is based on need for acute versus chronic treatment of blood pressures as well as safety. Medications used for acute lowering of blood pressure in pregnancy include intravenous <a class="drug drug_general" data-topicid="9540" href="/d/drug information/9540.html" rel="external">labetalol</a>, intravenous <a class="drug drug_general" data-topicid="8528" href="/d/drug information/8528.html" rel="external">hydralazine</a>, or oral <a class="drug drug_general" data-topicid="9700" href="/d/drug information/9700.html" rel="external">nifedipine</a>  (<a class="graphic graphic_table graphicRef110261" href="/d/graphic/110261.html" rel="external">table 6</a>). In a meta-analysis of 35 randomized trials involving 3573 pregnant patients comparing one antihypertensive agent against another, no agent was clearly superior [<a href="#rid61">61</a>]. Thus, the choice of antihypertensive agent should depend on availability, the clinician's experience and familiarity with a particular drug, and adverse effects.</p><p class="headingAnchor" id="H688801762"><span class="h4">Nonsevere hypertension</span></p><p class="headingAnchor" id="H576406909"><span class="h5">Patient subgroups</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients not on antihypertensive therapy and with no end-organ disease</strong> – For patients with chronic hypertension not on antihypertensive therapy and with no end-organ involvement, we recommend initiating treatment at blood pressure threshold of 140/90 mmHg using the fewest medications at the lowest effective dose to achieve this goal. Our approach is based on the benefits demonstrated in the Chronic Hypertension and Pregnancy (CHAP) trial [<a href="#rid62">62</a>] (See <a class="local">'Evidence of potential benefits of treatment'</a> below.) </p><p></p><p class="bulletIndent1">A target blood pressure range of 120 to 139/80 to 89 mmHg after initiation of treatment is reasonable, although specific target blood pressure range was not fully addressed in the CHAP trial.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients on antihypertensive therapy and with no end-organ disease</strong> – For patients with nonsevere hypertension on antihypertensive therapy with no end-organ involvement, our decision making is individualized. For most women with well-controlled blood pressures on an antihypertensive medication regimen with a good safety profile, it is reasonable to continue medications to decrease the occurrence of severe hypertension. A target blood pressure range of 120 to 139/80 to 89 mmHg is reasonable. However, it is also reasonable to discontinue medications during the first trimester to minimize fetal exposure and restart them if blood pressures meet the 140/90 mmHg threshold. With this approach, close blood pressure monitoring is imperative, and the blood pressure changes, such as the decline in the midtrimester and rise in the third trimester, must be considered. (See <a class="local">'Choice of drug and dosing'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with end-organ disease</strong> – For patients with nonsevere hypertension and end-organ involvement, such as heart or kidney disease, blood pressure management is paramount as uncontrolled hypertension may be associated with significant morbidity (see <a class="local">'Choice of drug and dosing'</a> below). After initiation of therapy, at a minimum, it is desirable to maintain blood pressure at 120 to 139/80 to 89 mmHg; whether lowering blood pressure to a "normal" level (ie, &lt;120/80 mmHg) would confer maternal benefit is unresolved [<a href="#rid20">20</a>]. The American Diabetes Association suggests treating pregnant patients with diabetes and hypertension, with the blood pressure target of 110 to 135/85 mmHg to reduce the risk for accelerated maternal hypertension and minimize impaired fetal growth [<a href="#rid63">63</a>]. (See  <a class="medical medical_review" href="/d/html/3829.html" rel="external">"Treatment of hypertension in patients with diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1">The CHAP trial excluded patients with secondary hypertension or other significant comorbidities (eg, heart or kidney disease), thus the impact of antihypertensive therapy and optimal blood pressure target in these patients could not be evaluated [<a href="#rid62">62</a>].</p><p></p><p class="headingAnchor" id="H3671505901"><span class="h5">Choice of drug and dosing</span><span class="headingEndMark"> — </span>In patients with nonsevere hypertension, our preference is to start treatment with either <a class="drug drug_general" data-topicid="9540" href="/d/drug information/9540.html" rel="external">labetalol</a>, a long-acting calcium channel blocker (eg, extended-release <a class="drug drug_general" data-topicid="9700" href="/d/drug information/9700.html" rel="external">nifedipine</a>), or <a class="drug drug_general" data-topicid="9635" href="/d/drug information/9635.html" rel="external">methyldopa</a>  (<a class="graphic graphic_table graphicRef55212" href="/d/graphic/55212.html" rel="external">table 7</a>). The dose is increased if at least two blood pressure measurements remain elevated. If maximum doses of one drug are ineffective to achieve the goal blood pressure range as discussed above, then a second or third drug can be added. It is important to closely monitor patients in whom blood pressure is not responding well to antihypertensive therapy since this may be a sign of preeclampsia. (See <a class="local">'Clinical presentation and evaluation'</a> below.)</p><p class="headingAnchor" id="H1212229965"><span class="h5">Evidence of potential benefits of treatment</span></p><p class="bulletIndent1"><span class="glyph">●</span>In the 2022 open-label, multicenter, pragmatic Chronic Hypertension and Pregnancy (CHAP) trial, 2408 pregnant people &lt;23 weeks of gestation with nonsevere chronic hypertension at 61 centers were randomly assigned to receive antihypertensive therapy at a threshold of 140/90 mmHg (active treatment) or no treatment until development of severe hypertension (defined as systolic BP≥160 or diastolic BP≥105 mmHg) (control group) [<a href="#rid62">62</a>]. Rates of the primary composite outcome (preeclampsia with severe features, medically indicated preterm birth at &lt;35 weeks of gestation, abruption, or fetal or neonatal death) were reduced in the active treatment group (30.2 versus 37.0 percent; adjusted risk ratio [aRR] 0.82, 95% CI 0.74-0.92), with no significant difference in rates of fetal growth restriction or serious neonatal or maternal morbidity. This trial represents the most robust evidence to inform clinical practice. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a 2022 network meta-analysis of 72 randomized trials (pre-CHAP) including nearly 7000 participants addressing which antihypertensives are superior to placebo/no therapy or another antihypertensive drug for controlling nonsevere pregnancy hypertension, major findings were [<a href="#rid64">64</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Commonly used antihypertensive drugs reduced the occurrence of severe hypertension by 30 to 70 percent compared with placebo/no treatment</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Labetalol reduced proteinuria/preeclampsia (odds ratio [OR] 0.73, 95% CI 0.54-0.99) and fetal/newborn death (OR 0.54, 95% CI 0.30-0.98) compared with placebo/no therapy</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Labetalol reduced proteinuria/preeclampsia compared with <a class="drug drug_general" data-topicid="9635" href="/d/drug information/9635.html" rel="external">methyldopa</a> (OR 0.66, 95% CI 0.44-0.99) and calcium channel blockers (OR 0.63, 95% CI 0.41–0.96). </p><p></p><p class="bulletIndent1">No other differences were identified. The possible benefit of <a class="drug drug_general" data-topicid="9540" href="/d/drug information/9540.html" rel="external">labetalol</a> over other antihypertensive drugs should be interpreted with caution given the wide confidence intervals.</p><p></p><p>Beyond noted benefits reflected in trial data, prevention of severe hypertension in pregnant individuals with chronic hypertension may have additional benefits. Experts point out that the failure to identify and treat severe maternal hypertension has been recognized in reviews of maternal deaths as the single most important failure in the care of patients with pregnancy-associated hypertension [<a href="#rid65">65</a>].</p><p class="headingAnchor" id="H285395296"><span class="h5">Evidence of potential harms of treatment</span><span class="headingEndMark"> — </span>The international multicenter randomized Control of Hypertension in Pregnancy (CHIPS) trial was designed to test the effects of less tight control (target diastolic blood pressure 100 mmHg) versus tight control (target diastolic blood pressure 85 mmHg) on pregnancy complications [<a href="#rid65">65,66</a>]. Most (75 percent) of the 987 participants in the trial had chronic hypertension. In a subgroup analysis of patients with chronic hypertension, less tight blood pressure control reduced the odds of small for gestational age (SGA) birth weight, with the upper confidence interval just missing statistical significance (aOR 0.66, 95% CI 0.44-1.00). However, key concerns have been raised with respect to extrapolating the results of CHIPS to patients with mild and moderate chronic hypertension. For example, the sample size of this subgroups of patients was inadequate to evaluate key perinatal outcomes such as SGA and indicated preterm birth. In addition, only a small percentage of patients with mild and moderate hypertension were enrolled prior to 20 weeks, and over one-half of the patients stayed on antihypertensive therapy at randomization, so there was inadequate comparison between antihypertensive therapy and no therapy. </p><p>In light of these concerns as well as newer data from the CHAP trial showing no increase in rates of fetal growth restriction with a 140/90 mmHg threshold for antihypertensive treatment in pregnant people with chronic hypertension, we believe that the association between tight control and SGA found in the subset of patients with chronic hypertension enrolled in CHIPS does not justify withholding antihypertensive treatment for blood pressures exceeding 140/90 mmHg.</p><p class="headingAnchor" id="H1670983047"><span class="h4">Recommendations of selected medical organizations</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>American College of Obstetricians and Gynecologists (ACOG) </strong>– ACOG has recommended utilizing 140/90 mmHg as the threshold for initiation or titration of medical therapy for chronic hypertension in pregnancy, rather than the previously recommended threshold of 160/110 mmHg [<a href="#rid67">67</a>]. ACOG has not made specific recommendations for patients with end-organ involvement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>National Institute for Health and Care Excellence (NICE)</strong> – NICE guidelines recommend offering treatment for systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg, with goal blood pressures of &lt;135/85 mmHg [<a href="#rid60">60</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>International Society for the Study of Hypertension in Pregnancy (ISSHP)</strong> – The ISSHP recommends pharmacologic therapy to keep blood pressures in the range of 110 to 140 mmHg/80 to 85 mmHg during pregnancy [<a href="#rid59">59</a>]. </p><p></p><p class="headingAnchor" id="H3056034693"><span class="h3">Screening for fetal growth restriction</span><span class="headingEndMark"> — </span>Our general approach to screening for fetal growth restriction (FGR) in patients with chronic hypertension is to perform serial ultrasound examinations to monitor fetal growth every three to four weeks. We initiate sonographic screening for FGR at 28 to 32 weeks but will perform an earlier examination if there is a clinical suspicion of FGR (eg, size &lt;&lt; dates).</p><p>Despite the consistent association between chronic hypertension and SGA in meta-analyses, the optimal timing and frequency of screening for FGR have not been determined. Furthermore, while it is generally accepted that detection of FGR and intervention (close monitoring, early delivery) will improve perinatal outcomes, several observational studies have failed to show a reduction in perinatal mortality [<a href="#rid68">68-70</a>] and others report that 75 to 80 percent of SGA newborns may not be detected antenatally [<a href="#rid71">71</a>]. (See  <a class="medical medical_review" href="/d/html/6752.html" rel="external">"Fetal growth restriction: Screening and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/6768.html" rel="external">"Fetal growth restriction: Evaluation"</a>.)</p><p class="headingAnchor" id="H633987195"><span class="h3">Tests to monitor fetal well-being</span><span class="headingEndMark"> — </span>We take the following approach to fetal surveillance in pregnancies complicated by chronic hypertension, while acknowledging the high degree of uncertainty regarding preferred strategies for optimizing perinatal outcomes:</p><p class="bulletIndent1"><span class="glyph">●</span>Kick counts – We suggest daily assessment of fetal kick counts starting at 28 weeks of gestation; &lt;10 fetal movements in two hours should prompt further assessment of fetal well-being. Maternal assessment of fetal movement, or fetal kick counts, is an inexpensive and easily implemented method to assess fetal well-being and, when normal, generally reassuring to mothers; however, its value for reducing perinatal mortality is unproven. (See  <a class="medical medical_review" href="/d/html/444.html" rel="external">"Decreased fetal movement: Diagnosis, evaluation, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>NST, BPP – As chronic hypertension has been consistently demonstrated to confer an increased risk for stillbirth (see <a class="local">'Fetal/neonatal risks'</a> above) and most studies have not distinguished between severe or mild hypertensive disease, we perform routine fetal surveillance on all pregnancies complicated by chronic hypertension. We initiate twice weekly fetal surveillance at 32 weeks of gestation because routine surveillance implemented earlier in gestation is unlikely to improve perinatal outcomes [<a href="#rid72">72</a>]. Twice weekly rather than weekly fetal testing is performed routinely based on limited evidence suggesting a reduction in fetal deaths with frequent testing [<a href="#rid73">73</a>]. Testing may be started earlier and performed more frequently in patients thought to be at high risk of early stillbirth. ACOG recommends antenatal fetal surveillance for pregnant individuals with chronic hypertension who need medication or who have fetal growth restriction, superimposed preeclampsia, or underlying medical conditions that may affect fetal outcome, as these pregnancies are at increased risk for fetal demise [<a href="#rid74">74,75</a>]. For patients with hypertension that is well-controlled with medication, they suggest weekly testing beginning at 32 weeks; initiation and frequency of testing are individualized for patients with poorly controlled hypertension. </p><p></p><p class="bulletIndent1">Comparison of serial nonstress tests (NSTs), biophysical profiles (BPPs), or modified BPPs reveals no significant difference in perinatal mortality rates associated with any specific modality of fetal surveillance [<a href="#rid76">76</a>]. The choice among these tests should be based on provider preference and other local factors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Umbilical artery Doppler – In pregnancies with FGR, management based on umbilical artery Doppler ultrasound findings is recommended as it has been demonstrated to reduce perinatal mortality [<a href="#rid77">77-79</a>]. (See  <a class="medical medical_review" href="/d/html/6768.html" rel="external">"Fetal growth restriction: Evaluation"</a> and  <a class="medical medical_review" href="/d/html/6768.html" rel="external">"Fetal growth restriction: Evaluation", section on 'Umbilical artery Doppler'</a>.)</p><p></p><p class="headingAnchor" id="H3214298727"><span class="h3">Delivery</span></p><p class="headingAnchor" id="H992835353"><span class="h4">Timing</span></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest delivery at 39+0 to 39+6 weeks of gestation for patients with well-controlled chronic hypertension alone and no indications for earlier delivery (eg, uncontrolled hypertension, superimposed preeclampsia, previous stillbirth, abruption in the current or past pregnancy, FGR). </p><p></p><p class="bulletIndent1">An analysis of perinatal outcome data from over 170,000 patients with chronic hypertension (both with and without superimposed preeclampsia) concluded that delivery at 38+0 to 39+6 weeks appeared to provide the optimal trade-off between the risk of adverse fetal and adverse neonatal outcomes [<a href="#rid80">80</a>]. We prefer to wait until 39 weeks because of the clearly demonstrated risks associated with iatrogenic delivery before 39+0 weeks [<a href="#rid81">81,82</a>] and the increased likelihood of more favorable perinatal outcomes in patients with chronic hypertension alone.</p><p></p><p class="bulletIndent1">ACOG suggested the following approach for delivery of patients with chronic hypertension [<a href="#rid2">2</a>]: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>≥38+0 to 39+6<sup> </sup>weeks of gestation for patients not requiring medication</p><p class="bulletIndent2"><span class="glyph">•</span>≥37+0 to 39+0<sup> </sup>weeks for patients with hypertension controlled with medication</p><p class="bulletIndent2"><span class="glyph">•</span>34+0 to 36+6 weeks for patients with severe hypertension that is difficult to control</p><p></p><p class="bulletIndent1">The ranges allow for clinician judgment on a case-by-case basis, with consideration of factors such as steady-state levels of and trends in blood pressure, fetal growth and amniotic fluid volume, and cervical status. The Society of Obstetricians and Gynaecologists of Canada also states that patients with uncomplicated preexisting hypertension who are otherwise well should be considered for delivery at 38+0 to 39+6 weeks of gestation [<a href="#rid83">83</a>]. </p><p></p><p class="bulletIndent1">For patients with superimposed preeclampsia or other pregnancy complications, the timing of delivery should be decided on a case-by-case basis based on the type and severity of these complications. (See <a class="local">'Patients with superimposed preeclampsia'</a> below and  <a class="medical medical_review" href="/d/html/6803.html" rel="external">"Acute placental abruption: Management and long-term prognosis"</a> and  <a class="medical medical_review" href="/d/html/6827.html" rel="external">"Stillbirth: Incidence, risk factors, etiology, and prevention"</a> and  <a class="medical medical_review" href="/d/html/139556.html" rel="external">"Fetal growth restriction: Pregnancy management and outcome", section on 'Delivery'</a>.)</p><p></p><p class="headingAnchor" id="H2099363439"><span class="h4">Intrapartum care</span></p><p class="bulletIndent1"><span class="glyph">●</span>General principles – Intrapartum management of patients with chronic hypertension should be driven by the same principles guiding intrapartum management in the general obstetric population. Cesarean birth should be reserved for standard obstetric indications. (See  <a class="medical medical_review" href="/d/html/4445.html" rel="external">"Labor and delivery: Management of the normal first stage"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of hypertension – The goal of intrapartum blood pressure management is to prevent maternal cerebrovascular or coronary events while minimizing rapid fluctuations in blood pressure that could influence uterine perfusion [<a href="#rid61">61</a>]. Antihypertensive medication regimens started prior to labor should be continued intrapartum. Rapid-acting medications should be used for confirmed blood pressures ≥160 mmHg systolic or ≥110 mmHg diastolic; intravenous <a class="drug drug_general" data-topicid="9540" href="/d/drug information/9540.html" rel="external">labetalol</a> is our preferred first-line agent  (<a class="graphic graphic_table graphicRef110261" href="/d/graphic/110261.html" rel="external">table 6</a>) [<a href="#rid3">3</a>]. ACOG endorses use of immediate-release oral <a class="drug drug_general" data-topicid="9700" href="/d/drug information/9700.html" rel="external">nifedipine</a> as a first-line option for emergency treatment of acute, severe hypertension in pregnancy, particularly when intravenous access is not in place. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fluids – Volume status (fluid intake and output) should be recorded, with the goal of maintaining euvolemia. Maintenance of euvolemia during labor is particularly important in patients with a long-standing history of hypertension and left ventricular hypertrophy and/or diastolic dysfunction, as they are predisposed to pulmonary edema with volume overload, whereas volume depletion can lead to tachycardia and reduced filling times, exacerbating any preexisting diastolic dysfunction. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9585" href="/d/drug information/9585.html" rel="external">Magnesium sulfate</a> – Intrapartum magnesium sulfate therapy for seizure prophylaxis is not indicated in the absence of superimposed preeclampsia as the risk of having a seizure is less than 0.1 percent [<a href="#rid84">84</a>]. </p><p></p><p class="bulletIndent1">In patients with hypertension related to chronic kidney disease who are preterm and receiving <a class="drug drug_general" data-topicid="9585" href="/d/drug information/9585.html" rel="external">magnesium sulfate</a> for neonatal neuroprotection, close maternal monitoring is essential for prevention and early recognition of magnesium toxicity. (See <a class="local">'Management'</a> below and  <a class="medical medical_review" href="/d/html/139247.html" rel="external">"Preeclampsia: Intrapartum and postpartum management and long-term prognosis", section on 'Signs of magnesium toxicity'</a>.)</p><p></p><p class="headingAnchor" id="H228889627"><span class="h2">Patients with superimposed preeclampsia</span></p><p class="headingAnchor" id="H190274425"><span class="h3">Definition/diagnostic criteria</span><span class="headingEndMark"> — </span>Preeclampsia is considered superimposed when it occurs in a patient with previously diagnosed chronic hypertension. However, distinguishing superimposed preeclampsia from third-trimester physiologic increases in blood pressure and proteinuria can be challenging. </p><p>Superimposed preeclampsia is likely when any of the following are present:</p><p class="bulletIndent1"><span class="glyph">●</span>A sudden increase in blood pressure that was previously well-controlled or a need for a rapid escalation of antihypertensive medications to control blood pressure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The new onset of proteinuria or a sudden increase in proteinuria in a patient with known prepregnancy or early pregnancy proteinuria. A sudden increase in proteinuria is not precisely defined by various societies or in the existing literature. Based on limited evidence, we typically diagnose superimposed preeclampsia when the level of proteinuria increases 100 percent from baseline in patients with preexisting kidney disease or proteinuria [<a href="#rid85">85</a>].</p><p></p><p>The presence of any of the following severe features of preeclampsia supports the diagnosis of superimposed preeclampsia with severe features:</p><p class="bulletIndent1"><span class="glyph">●</span>Severely elevated blood pressure despite increasing antihypertensive therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thrombocytopenia (platelet count &lt;100,000/microliter).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated transaminases (two times the upper limit of the normal concentration for a particular laboratory) or severe persistent right upper quadrant or epigastric pain unresponsive to medication and not accounted for by alternative diagnoses, or both.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>New-onset or worsening renal insufficiency.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary edema.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Persistent cerebral or visual disturbances.</p><p></p><p>In the absence of severe features, there may be ambiguity in the diagnosis of superimposed preeclampsia. Given the risk of disease progression and adverse outcomes, increased vigilance is recommended whenever the diagnosis is suspected. </p><p class="headingAnchor" id="H3615776304"><span class="h3">Incidence and risk factors</span><span class="headingEndMark"> — </span>Superimposed preeclampsia develops in 13 to 40 percent of pregnant patients with chronic hypertension. The risk for developing superimposed preeclampsia is higher in patients with long-standing, severe, or secondary hypertension; obesity; Black race; history of preeclampsia; and smoking [<a href="#rid24">24</a>]. </p><p class="headingAnchor" id="H2248225999"><span class="h3">Clinical presentation and evaluation</span><span class="headingEndMark"> — </span>The clinical presentation of superimposed preeclampsia is similar to that in patients without chronic hypertension, and their evaluation should be the same. (See  <a class="medical medical_review" href="/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis", section on 'Clinical presentation'</a> and  <a class="medical medical_review" href="/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis", section on 'Patient evaluation'</a>.)</p><p>Results of laboratory testing should be compared with baseline information obtained early in pregnancy. As discussed above, new-onset proteinuria or a sudden large increase in protein excretion along with one or more features of severe disease strongly supports the diagnosis. However, in patients with long-standing kidney disease or kidney disease of unknown duration, changes in creatinine level and proteinuria should be cautiously interpreted before making a definitive diagnosis of superimposed preeclampsia. (See  <a class="medical medical_review" href="/d/html/126975.html" rel="external">"Hypertensive disorders in pregnancy: Approach to differential diagnosis"</a>.)</p><p class="headingAnchor" id="H998621229"><span class="h3">Management</span><span class="headingEndMark"> — </span>Upon diagnosis of superimposed preeclampsia, management of patients with chronic hypertension is generally similar to that of other patients with preeclampsia. (See  <a class="medical medical_review" href="/d/html/6825.html" rel="external">"Preeclampsia: Antepartum management and timing of delivery"</a>.)</p><p>Some considerations for patients with superimposed preeclampsia include:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with superimposed preeclampsia should initially be monitored in the inpatient setting. If there are no severe features, outpatient monitoring may be considered if the patient remains stable, has no severe features of preeclampsia, and is able to comply with self-monitoring and frequent visits. While outpatient care after a period of inpatient monitoring may be a reasonable option for patients with superimposed preeclampsia without severe features, those with severe features should be in the hospital until delivery. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As in patients with preeclampsia, administration of a course of antenatal corticosteroids to preterm gestations and antihypertensive therapy to patients with severe hypertension are important considerations. (See  <a class="medical medical_review" href="/d/html/6825.html" rel="external">"Preeclampsia: Antepartum management and timing of delivery", section on 'Components of expectant management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Timing and indications for delivery with superimposed preeclampsia are based on gestational age, disease severity, progression of disease, and results of ongoing assessment of maternal and fetal well-being. With any attempts to prolong pregnancy, the potential neonatal benefits must be weighed against the risk of maternal harm. (See  <a class="medical medical_review" href="/d/html/6825.html" rel="external">"Preeclampsia: Antepartum management and timing of delivery"</a>.)</p><p></p><p class="bulletIndent1">Data from small retrospective studies of patients with preterm superimposed preeclampsia with severe features suggest that outcomes with expectant management are similar to those in patients with preterm preeclampsia with severe features alone [<a href="#rid86">86,87</a>]. Although these studies are small and limited by their study design, it appears that a similar approach to management is reasonable. (See  <a class="medical medical_review" href="/d/html/6791.html" rel="external">"Preeclampsia with severe features: Delaying delivery in pregnancies remote from term"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The frequency of eclampsia in patients with superimposed preeclampsia is not well-defined but was up to 2.4 percent in observational and retrospective studies [<a href="#rid24">24,86</a>]. We administer <a class="drug drug_general" data-topicid="9585" href="/d/drug information/9585.html" rel="external">magnesium sulfate</a> peripartum for seizure prophylaxis to patients who have superimposed preeclampsia with severe features. In patients with chronic kidney disease on magnesium sulfate for prevention of seizures or fetal/neonatal neuroprotection, close maternal monitoring is essential for prevention and early recognition of magnesium toxicity. (See  <a class="medical medical_review" href="/d/html/139247.html" rel="external">"Preeclampsia: Intrapartum and postpartum management and long-term prognosis", section on 'Seizure prophylaxis'</a> and  <a class="medical medical_review" href="/d/html/139247.html" rel="external">"Preeclampsia: Intrapartum and postpartum management and long-term prognosis", section on 'Signs of magnesium toxicity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intrapartum and postpartum, volume status and fluid management are of particular importance as increased third-spacing from preeclampsia may predispose to pulmonary edema. (See  <a class="medical medical_review" href="/d/html/139247.html" rel="external">"Preeclampsia: Intrapartum and postpartum management and long-term prognosis", section on 'Fluids'</a>.)</p><p></p><p class="headingAnchor" id="H2270876862"><span class="h3">Recurrence risk</span><span class="headingEndMark"> — </span>Reports regarding the recurrence risk of superimposed preeclampsia are variable. In one study that was based on a secondary analysis of a larger antioxidant trial, patients with chronic hypertension and prior preeclampsia/HELLP/eclampsia had a 1.95-fold increase in risk of superimposed preeclampsia in a subsequent pregnancy compared with patients without prior preeclampsia/HELLP/eclampsia [<a href="#rid24">24</a>]. In contrast, a secondary analysis of a United States-based antioxidant trial found that the risk of superimposed preeclampsia was similar (28 percent, adjusted RR 1.28, 95% CI 0.78-2.11) in patients with chronic hypertension and prior preeclampsia versus those with no prior preeclampsia [<a href="#rid88">88</a>]. The risks for placental abruption, perinatal death, and SGA newborn were also similar for the two groups, but patients with prior preeclampsia had a higher rate of preterm birth &lt;37 weeks (36.9 versus 27.1 percent) and at 34 to 36 weeks (30.9 versus 18.3 percent). Counseling regarding future pregnancy risk can be based on these data and those available for chronic hypertension in pregnancy overall.</p><p class="headingAnchor" id="H3805416580"><span class="h1">POSTPARTUM CARE</span></p><p class="headingAnchor" id="H3115540479"><span class="h2">Analgesia</span><span class="headingEndMark"> — </span>The decision to use nonsteroidal anti-inflammatory drugs (NSAIDs) for analgesia should be individualized as these drugs are known to cause elevations in blood pressure in some nonpregnant individuals with hypertension. (See  <a class="medical medical_review" href="/d/html/2385.html" rel="external">"NSAIDs and acetaminophen: Effects on blood pressure and hypertension"</a>.)</p><p>Overall, the body of data supports the safe use of NSAIDs in postpartum patients with blood pressure issues [<a href="#rid89">89</a>] and their use in patients with hypertension is supported by the American College of Obstetricians and Gynecologists [<a href="#rid90">90</a>]. If blood pressure is elevated in the postpartum period, we use <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> as our first-line medication for pain management. NSAIDs should be used preferentially over opioid analgesics, when possible. However, we avoid post-delivery NSAID use in patients with preexisting kidney disease and/or elevated serum creatinine levels. (See  <a class="medical medical_review" href="/d/html/6815.html" rel="external">"Treatment of hypertension in pregnant and postpartum patients", section on 'Management'</a>.)</p><p class="headingAnchor" id="H1909656063"><span class="h2">Blood pressure management</span><span class="headingEndMark"> — </span>Blood pressure control is an ongoing issue during the postpartum period, even in patients with chronic hypertension who did not require antihypertensive therapy during pregnancy. Blood pressure often declines immediately after giving birth and continues to decline for a few days before increasing three to five days postpartum when the patient may already be at home [<a href="#rid91">91</a>]. The immediate decline is generally attributed to blood loss and the effects of analgesia, while the subsequent increase is likely due to mobilization of extravascular fluid with a rise in intravascular volume, as well as factors such as pain.</p><p>Early postpartum visits for a blood pressure check (within 3 to 10 days after giving birth [<a href="#rid2">2</a>]) or home blood pressure monitoring, particularly in the first two weeks postpartum, is recommended. Home blood pressure monitoring strategies are likely to be helpful given the often suboptimal compliance with postpartum visits [<a href="#rid92">92</a>]. The risk for developing severe hypertension postpartum was illustrated in a retrospective cohort study of 235 patients with chronic hypertension in which 13 percent developed severe hypertension postpartum [<a href="#rid93">93</a>]. At discharge, these patients had mean systolic and diastolic blood pressures of 141 and 78 mmHg, respectively, and 87 percent were discharged on antihypertensive medications.</p><p>Choice of medications for blood pressure control is the same as during pregnancy, or the patient's prepregnancy antihypertensive regimen can be resumed after delivery, with consideration of safety in breastfeeding when relevant. Dose adjustments of antepartum regimens may be needed to reflect the decrease in volume of distribution and glomerular filtration rate that occurs after giving birth [<a href="#rid94">94</a>]. If volume overload is suspected or diagnosed, then diuresis should be considered, such as with a brief course of <a class="drug drug_general" data-topicid="8482" href="/d/drug information/8482.html" rel="external">furosemide</a>. (See  <a class="medical medical_review" href="/d/html/6815.html" rel="external">"Treatment of hypertension in pregnant and postpartum patients", section on 'Approach to patients with severe versus nonsevere hypertension'</a>.)</p><p>Extended postpartum follow-up is important. A population-based retrospective cohort study found that postpartum hospitalization for cardiovascular disease (CVD) within one year after delivery was higher among patients with chronic hypertension than for normotensive patients (645 versus 136 per 100,000 delivery hospitalizations; adjusted hazard ratio 4.11, 95% CI 3.64-4.66) and the risk for readmission for CVD persisted for the entire year after giving birth [<a href="#rid95">95</a>]. (See <a class="local">'Referral for primary care'</a> below.)</p><p class="headingAnchor" id="H1689100781"><span class="h2">Family planning</span><span class="headingEndMark"> — </span>Contraception and appropriate timing of future pregnancies should be discussed. Estrogen-containing contraceptive agents are generally avoided in patients with stage 2 hypertension or higher (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg) even if well-controlled because the theoretic or proven risks generally exceed the benefits, and good alternatives are available. (See  <a class="medical medical_review" href="/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Eligibility criteria (WHO and CDC)'</a>.)</p><p class="headingAnchor" id="H3454111084"><span class="h2">Referral for primary care</span><span class="headingEndMark"> — </span>Patients with known chronic hypertension should resume care with their primary care provider postpartum. Patients with chronic hypertension first diagnosed during pregnancy or in the postpartum period based on persistently elevated blood pressure 12 weeks after giving birth should be referred to a primary care provider for ongoing management of hypertension, which may persist or resolve. (See  <a class="medical medical_review" href="/d/html/6815.html" rel="external">"Treatment of hypertension in pregnant and postpartum patients", section on 'Development of hypertension in nonpregnant patients after hypertension first presenting in pregnancy'</a>.)</p><p>The pregnancy/postpartum time frame is an opportunity to educate patients regarding the long-term risks of hypertension and the importance of ongoing care, which may help to ensure follow-up with a primary care provider for long-term management of chronic hypertension and cardiovascular risks. Progression from mild to severe hypertension within seven years is common [<a href="#rid96">96</a>]. (See  <a class="medical medical_review" href="/d/html/3852.html" rel="external">"Overview of hypertension in adults"</a>.)</p><p class="headingAnchor" id="H536080526"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109729.html" rel="external">"Society guideline links: Hypertensive disorders of pregnancy"</a>.)</p><p class="headingAnchor" id="H1888687279"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Blood pressure criteria for hypertension in pregnancy are systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or both. Severe hypertension is defined as systolic blood pressure ≥160 mmHg, diastolic blood pressure ≥110 mmHg, or both. Diagnostic definitions/criteria for the various hypertensive disorders related to pregnancy are described in the table  (<a class="graphic graphic_table graphicRef127246" href="/d/graphic/127246.html" rel="external">table 2</a>). (See <a class="local">'Definition/diagnostic criteria'</a> above.)</p><p></p><p class="bulletIndent1">The diagnosis of superimposed preeclampsia is challenging in the absence of severe features of preeclampsia. Given the risk of disease progression and adverse outcomes, increased vigilance is recommended whenever the diagnosis is suspected. Management is the same as that in other patients with preeclampsia. (See <a class="local">'Patients with superimposed preeclampsia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview of management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preconception</strong> – Ideally, patients with chronic hypertension are assessed prior to conception to address the issues described in the table  (<a class="graphic graphic_table graphicRef127249" href="/d/graphic/127249.html" rel="external">table 3</a>), in addition to routine preconception assessments. Maternal-fetal medicine consultation should be considered for counseling and management both preconception and during pregnancy. (See <a class="local">'Preconception care'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Early pregnancy evaluations</strong> – Baseline laboratory and cardiac evaluation is repeated at the first prenatal visit  (<a class="graphic graphic_table graphicRef127249" href="/d/graphic/127249.html" rel="external">table 3</a>), if not recently performed. In addition, accurate gestational dating is important since these pregnancies are at increased risk for developing fetal growth restriction (FGR) and undergoing obstetrically indicated preterm birth. (See <a class="local">'Baseline clinical evaluation, laboratory testing, and preeclampsia prophylaxis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Low-dose </strong><a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a><strong> prophylaxis</strong> – Low-dose aspirin is recommended after 12 weeks of gestation for prevention of preeclampsia as these patients are at high risk of developing the disease. (See  <a class="medical medical_review" href="/d/html/6817.html" rel="external">"Preeclampsia: Prevention", section on 'Low-dose aspirin'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monitoring for FGR and evaluation of fetal wellbeing</strong> – We monitor for FGR beginning at 28 to 32 weeks and initiate twice weekly nonstress tests or biophysical profiles at 32 weeks. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Timing of delivery</strong> – We suggest delivery at 39+0 to 39+6 weeks of gestation for patients with well-controlled chronic hypertension alone and no standard indications for earlier delivery. (See <a class="local">'Timing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Use of intrapartum </strong><a class="drug drug_general" data-topicid="9585" href="/d/drug information/9585.html" rel="external">magnesium sulfate</a> – Intrapartum magnesium sulfate therapy for seizure prophylaxis is not indicated in the absence of superimposed preeclampsia. Antihypertensive medication regimens started prior to labor should be continued intrapartum, and severe hypertension should be treated promptly  (<a class="graphic graphic_table graphicRef110261" href="/d/graphic/110261.html" rel="external">table 6</a>). (See <a class="local">'Intrapartum care'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Postpartum monitoring</strong> – Postpartum visits for a blood pressure check within 3 to 10 days after giving birth or home blood pressure monitoring is recommended as severe hypertension can develop after hospital discharge. (See <a class="local">'Blood pressure management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of hypertension</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe hypertension</strong> – Severe maternal hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥110 mmHg) should be pharmacologically treated in a timely manner to reduce the risk for stroke. Options for drug therapy are shown in the table  (<a class="graphic graphic_table graphicRef110261" href="/d/graphic/110261.html" rel="external">table 6</a>). (See <a class="local">'Severe hypertension'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonsevere hypertension</strong> – Our approach to women with nonsevere chronic hypertension depends on whether there is end-organ involvement. Oral antihypertensive therapy dosing is shown in the table  (<a class="graphic graphic_table graphicRef55212" href="/d/graphic/55212.html" rel="external">table 7</a>). (See <a class="local">'Nonsevere hypertension'</a> above.)</p><p></p><p class="bulletIndent2">No end-organ involvement:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with nonsevere hypertension, not on antihypertensive therapy, and with no end-organ involvement, we utilize 140/90 mmHg as the threshold for initiation of medical therapy for chronic hypertension in pregnancy. We use the fewest medications at the lowest effective dose to achieve this goal.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with nonsevere hypertension, on antihypertensive therapy, and with no end-organ involvement, our decision making is individualized. For most patients with well-controlled blood pressures on an antihypertensive medication regimen with a good safety profile, it is reasonable to continue medications to decrease the occurrence of severe hypertension. A target blood pressure range of 120 to 139/80 to 89 mmHg is reasonable. However, it is also reasonable to discontinue medications during the first trimester to minimize fetal exposure and restart them if blood pressures meet the 140/90 mmHg threshold. With this approach, close blood pressure monitoring is imperative, and the blood pressure changes, such as the decline in the midtrimester and rise in the third trimester, must be considered. </p><p></p><p class="bulletIndent2">End-organ involvement:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with nonsevere hypertension and end-organ involvement, our target blood pressure is 120 to 139/80 to 89 mmHg. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy outcome</strong> – Chronic hypertension is associated with substantial maternal and fetal/neonatal morbidity and mortality  (<a class="graphic graphic_table graphicRef127248" href="/d/graphic/127248.html" rel="external">table 1</a>). Superimposed preeclampsia increases the risk of adverse outcomes. (See <a class="local">'Risks of chronic hypertension in pregnancy'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Tranquilli AL, Dekker G, Magee L, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens 2014; 4:97.</a></li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy. Obstet Gynecol 2019; 133:e26.</a></li><li><a class="nounderline abstract_t">ACOG Committee Opinion No. 767 Summary: Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period. Obstet Gynecol 2019; 133:409.</a></li><li><a class="nounderline abstract_t">Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71:1269.</a></li><li class="breakAll">NHLBI. Prevention, Detection, Evaluation, and Treatment of High Blood Pressure The Seventh Report of the Joint National Committee on Complete Report. https://www.nhlbi.nih.gov/files/docs/guidelines/jnc7full.pdf (Accessed on March 03, 2020).</li><li><a class="nounderline abstract_t">Topel ML, Duncan EM, Krishna I, et al. Estimated Impact of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guidelines on Reproductive-Aged Women. Hypertension 2018; 72:e39.</a></li><li><a class="nounderline abstract_t">Bello NA, Zhou H, Cheetham TC, et al. Prevalence of Hypertension Among Pregnant Women When Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guidelines and Association With Maternal and Fetal Outcomes. JAMA Netw Open 2021; 4:e213808.</a></li><li><a class="nounderline abstract_t">Slade LJ, Wilson M, Mistry HD, et al. The 2017 American College of Cardiology and American Heart Association blood pressure categories in the second half of pregnancy-a systematic review of their association with adverse pregnancy outcomes. Am J Obstet Gynecol 2023; 229:101.</a></li><li><a class="nounderline abstract_t">Ford ND, Cox S, Ko JY, et al. Hypertensive Disorders in Pregnancy and Mortality at Delivery Hospitalization - United States, 2017-2019. MMWR Morb Mortal Wkly Rep 2022; 71:585.</a></li><li><a class="nounderline abstract_t">Bateman BT, Bansil P, Hernandez-Diaz S, et al. Prevalence, trends, and outcomes of chronic hypertension: a nationwide sample of delivery admissions. Am J Obstet Gynecol 2012; 206:134.e1.</a></li><li><a class="nounderline abstract_t">Creanga AA, Syverson C, Seed K, Callaghan WM. Pregnancy-Related Mortality in the United States, 2011-2013. Obstet Gynecol 2017; 130:366.</a></li><li><a class="nounderline abstract_t">Sibai BM, Lindheimer M, Hauth J, et al. Risk factors for preeclampsia, abruptio placentae, and adverse neonatal outcomes among women with chronic hypertension. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1998; 339:667.</a></li><li><a class="nounderline abstract_t">Ferrer RL, Sibai BM, Mulrow CD, et al. Management of mild chronic hypertension during pregnancy: a review. Obstet Gynecol 2000; 96:849.</a></li><li><a class="nounderline abstract_t">Ananth CV, Duzyj CM, Yadava S, et al. Changes in the Prevalence of Chronic Hypertension in Pregnancy, United States, 1970 to 2010. Hypertension 2019; 74:1089.</a></li><li><a class="nounderline abstract_t">Panaitescu AM, Syngelaki A, Prodan N, et al. Chronic hypertension and adverse pregnancy outcome: a cohort study. Ultrasound Obstet Gynecol 2017; 50:228.</a></li><li><a class="nounderline abstract_t">Vanek M, Sheiner E, Levy A, Mazor M. Chronic hypertension and the risk for adverse pregnancy outcome after superimposed pre-eclampsia. Int J Gynaecol Obstet 2004; 86:7.</a></li><li><a class="nounderline abstract_t">Zetterström K, Lindeberg SN, Haglund B, Hanson U. Maternal complications in women with chronic hypertension: a population-based cohort study. Acta Obstet Gynecol Scand 2005; 84:419.</a></li><li><a class="nounderline abstract_t">Williams MA, Mittendorf R, Monson RR. Chronic hypertension, cigarette smoking, and abruptio placentae. Epidemiology 1991; 2:450.</a></li><li><a class="nounderline abstract_t">Ankumah NA, Cantu J, Jauk V, et al. Risk of adverse pregnancy outcomes in women with mild chronic hypertension before 20 weeks of gestation. Obstet Gynecol 2014; 123:966.</a></li><li><a class="nounderline abstract_t">Sibai BM. Chronic hypertension in pregnancy. Obstet Gynecol 2002; 100:369.</a></li><li><a class="nounderline abstract_t">Nzelu D, Dumitrascu-Biris D, Nicolaides KH, Kametas NA. Chronic hypertension: first-trimester blood pressure control and likelihood of severe hypertension, preeclampsia, and small for gestational age. Am J Obstet Gynecol 2018; 218:337.e1.</a></li><li><a class="nounderline abstract_t">Magee LA, von Dadelszen P, Singer J, et al. The CHIPS Randomized Controlled Trial (Control of Hypertension in Pregnancy Study): Is Severe Hypertension Just an Elevated Blood Pressure? Hypertension 2016; 68:1153.</a></li><li><a class="nounderline abstract_t">Battarbee AN, Sinkey RG, Harper LM, et al. Chronic hypertension in pregnancy. Am J Obstet Gynecol 2020; 222:532.</a></li><li><a class="nounderline abstract_t">Chappell LC, Enye S, Seed P, et al. Adverse perinatal outcomes and risk factors for preeclampsia in women with chronic hypertension: a prospective study. Hypertension 2008; 51:1002.</a></li><li><a class="nounderline abstract_t">Bramham K, Parnell B, Nelson-Piercy C, et al. Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis. BMJ 2014; 348:g2301.</a></li><li><a class="nounderline abstract_t">Ananth CV, Smulian JC, Vintzileos AM. Incidence of placental abruption in relation to cigarette smoking and hypertensive disorders during pregnancy: a meta-analysis of observational studies. Obstet Gynecol 1999; 93:622.</a></li><li><a class="nounderline abstract_t">Rey E, Couturier A. The prognosis of pregnancy in women with chronic hypertension. Am J Obstet Gynecol 1994; 171:410.</a></li><li><a class="nounderline abstract_t">Zetterström K, Lindeberg SN, Haglund B, Hanson U. The association of maternal chronic hypertension with perinatal death in male and female offspring: a record linkage study of 866,188 women. BJOG 2008; 115:1436.</a></li><li><a class="nounderline abstract_t">Flenady V, Koopmans L, Middleton P, et al. Major risk factors for stillbirth in high-income countries: a systematic review and meta-analysis. Lancet 2011; 377:1331.</a></li><li><a class="nounderline abstract_t">McCowan LM, Buist RG, North RA, Gamble G. Perinatal morbidity in chronic hypertension. Br J Obstet Gynaecol 1996; 103:123.</a></li><li><a class="nounderline abstract_t">Sibai BM, Anderson GD. Pregnancy outcome of intensive therapy in severe hypertension in first trimester. Obstet Gynecol 1986; 67:517.</a></li><li><a class="nounderline abstract_t">Ramakrishnan A, Lee LJ, Mitchell LE, Agopian AJ. Maternal Hypertension During Pregnancy and the Risk of Congenital Heart Defects in Offspring: A Systematic Review and Meta-analysis. Pediatr Cardiol 2015; 36:1442.</a></li><li><a class="nounderline abstract_t">Bateman BT, Huybrechts KF, Fischer MA, et al. Chronic hypertension in pregnancy and the risk of congenital malformations: a cohort study. Am J Obstet Gynecol 2015; 212:337.e1.</a></li><li><a class="nounderline abstract_t">van Gelder MM, Van Bennekom CM, Louik C, et al. Maternal hypertensive disorders, antihypertensive medication use, and the risk of birth defects: a case-control study. BJOG 2015; 122:1002.</a></li><li><a class="nounderline abstract_t">Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007; 335:974.</a></li><li><a class="nounderline abstract_t">McDonald SD, Malinowski A, Zhou Q, et al. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J 2008; 156:918.</a></li><li><a class="nounderline abstract_t">Wu P, Haththotuwa R, Kwok CS, et al. Preeclampsia and Future Cardiovascular Health: A Systematic Review and Meta-Analysis. Circ Cardiovasc Qual Outcomes 2017; 10.</a></li><li><a class="nounderline abstract_t">Luoto R, Kharazmi E, Whitley E, et al. Systolic hypertension in pregnancy and cardiovascular mortality: a 44-year follow-up study. Hypertens Pregnancy 2008; 27:87.</a></li><li><a class="nounderline abstract_t">Cirillo PM, Cohn BA. Pregnancy complications and cardiovascular disease death: 50-year follow-up of the Child Health and Development Studies pregnancy cohort. Circulation 2015; 132:1234.</a></li><li><a class="nounderline abstract_t">Tuovinen S, Räikkönen K, Pesonen AK, et al. Hypertensive disorders in pregnancy and risk of severe mental disorders in the offspring in adulthood: the Helsinki Birth Cohort Study. J Psychiatr Res 2012; 46:303.</a></li><li><a class="nounderline abstract_t">Tuovinen S, Eriksson JG, Kajantie E, et al. Maternal hypertensive disorders in pregnancy and self-reported cognitive impairment of the offspring 70 years later: the Helsinki Birth Cohort Study. Am J Obstet Gynecol 2013; 208:200.e1.</a></li><li><a class="nounderline abstract_t">Tuovinen S, Räikkönen K, Kajantie E, et al. Hypertensive disorders in pregnancy and cognitive decline in the offspring up to old age. Neurology 2012; 79:1578.</a></li><li><a class="nounderline abstract_t">Kanata M, Liazou E, Chainoglou A, et al. Clinical outcomes of hypertensive disorders in pregnancy in the offspring during perinatal period, childhood, and adolescence. J Hum Hypertens 2021; 35:1063.</a></li><li><a class="nounderline abstract_t">Li DK, Yang C, Andrade S, et al. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ 2011; 343:d5931.</a></li><li><a class="nounderline abstract_t">Laube GF, Kemper MJ, Schubiger G, Neuhaus TJ. Angiotensin-converting enzyme inhibitor fetopathy: long-term outcome. Arch Dis Child Fetal Neonatal Ed 2007; 92:F402.</a></li><li><a class="nounderline abstract_t">Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006; 354:2443.</a></li><li><a class="nounderline abstract_t">US Preventive Services Task Force, Davidson KW, Barry MJ, et al. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement. JAMA 2021; 326:1186.</a></li><li><a class="nounderline abstract_t">Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol 2018; 218:287.</a></li><li><a class="nounderline abstract_t">Richards EMF, Giorgione V, Stevens O, Thilaganathan B. Low-dose aspirin for the prevention of superimposed preeclampsia in women with chronic hypertension: a systematic review and meta-analysis. Am J Obstet Gynecol 2023; 228:395.</a></li><li><a class="nounderline abstract_t">Fulay AP, Rifas-Shiman SL, Oken E, Perng W. Associations of the dietary approaches to stop hypertension (DASH) diet with pregnancy complications in Project Viva. Eur J Clin Nutr 2018; 72:1385.</a></li><li><a class="nounderline abstract_t">Aubert AM, Forhan A, de Lauzon-Guillain B, et al. Deriving the Dietary Approaches to Stop Hypertension (DASH) Score in Women from Seven Pregnancy Cohorts from the European ALPHABET Consortium. Nutrients 2019; 11.</a></li><li><a class="nounderline abstract_t">Jiang F, Li Y, Xu P, et al. The efficacy of the Dietary Approaches to Stop Hypertension diet with respect to improving pregnancy outcomes in women with hypertensive disorders. J Hum Nutr Diet 2019; 32:713.</a></li><li><a class="nounderline abstract_t">Brand A, Visser ME, Schoonees A, Naude CE. Replacing salt with low-sodium salt substitutes (LSSS) for cardiovascular health in adults, children and pregnant women. Cochrane Database Syst Rev 2022; 8:CD015207.</a></li><li><a class="nounderline abstract_t">ACOG Practice Bulletin No. 203 Summary: Chronic Hypertension in Pregnancy. Obstet Gynecol 2019; 133:215.</a></li><li><a class="nounderline abstract_t">Bello NA, Woolley JJ, Cleary KL, et al. Accuracy of Blood Pressure Measurement Devices in Pregnancy: A Systematic Review of Validation Studies. Hypertension 2018; 71:326.</a></li><li><a class="nounderline abstract_t">Tucker KL, Bankhead C, Hodgkinson J, et al. How Do Home and Clinic Blood Pressure Readings Compare in Pregnancy? Hypertension 2018; 72:686.</a></li><li><a class="nounderline abstract_t">Kalafat E, Benlioglu C, Thilaganathan B, Khalil A. Home blood pressure monitoring in the antenatal and postpartum period: A systematic review meta-analysis. Pregnancy Hypertens 2020; 19:44.</a></li><li><a class="nounderline abstract_t">Tran K, Padwal R, Khan N, et al. Home blood pressure monitoring in the diagnosis and treatment of hypertension in pregnancy: a systematic review and meta-analysis. CMAJ Open 2021; 9:E642.</a></li><li><a class="nounderline abstract_t">Brown MA, Magee LA, Kenny LC, et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis &amp; management recommendations for international practice. Pregnancy Hypertens 2018; 13:291.</a></li><li><a class="nounderline abstract_t">Webster K, Fishburn S, Maresh M, et al. Diagnosis and management of hypertension in pregnancy: summary of updated NICE guidance. BMJ 2019; 366:l5119.</a></li><li><a class="nounderline abstract_t">Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev 2013; :CD001449.</a></li><li><a class="nounderline abstract_t">Tita AT, Szychowski JM, Boggess K, et al. Treatment for Mild Chronic Hypertension during Pregnancy. N Engl J Med 2022; 386:1781.</a></li><li><a class="nounderline abstract_t">American Diabetes Association Professional Practice Committee. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2024. Diabetes Care 2024; 47:S282.</a></li><li><a class="nounderline abstract_t">Bone JN, Sandhu A, Abalos ED, et al. Oral Antihypertensives for Nonsevere Pregnancy Hypertension: Systematic Review, Network Meta- and Trial Sequential Analyses. Hypertension 2022; 79:614.</a></li><li><a class="nounderline abstract_t">Magee LA, Singer J, von Dadelszen P, CHIPS Study Group. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med 2015; 372:2367.</a></li><li><a class="nounderline abstract_t">Magee LA, von Dadelszen P, Rey E, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med 2015; 372:407.</a></li><li class="breakAll">Clinical Guidance for the Integration of the Findings of the Chronic Hypertension and Pregnancy (CHAP) Study. American College of Obstetricians and Gynecologists. 2022. Available at: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2022/04/clinical-guidance-for-the-integration-of-the-findings-of-the-chronic-hypertension-and-pregnancy-chap-study (Accessed on May 02, 2022).</li><li><a class="nounderline abstract_t">Larkin JC, Chauhan SP, Simhan HN. Small for Gestational Age: The Differential Mortality When Detected versus Undetected Antenatally. Am J Perinatol 2017; 34:409.</a></li><li><a class="nounderline abstract_t">Bricker L, Neilson JP, Dowswell T. Routine ultrasound in late pregnancy (after 24 weeks' gestation). Cochrane Database Syst Rev 2008; :CD001451.</a></li><li><a class="nounderline abstract_t">Imdad A, Yakoob MY, Siddiqui S, Bhutta ZA. Screening and triage of intrauterine growth restriction (IUGR) in general population and high risk pregnancies: a systematic review with a focus on reduction of IUGR related stillbirths. BMC Public Health 2011; 11 Suppl 3:S1.</a></li><li><a class="nounderline abstract_t">Vieira MC, Relph S, Muruet-Gutierrez W, et al. Evaluation of the Growth Assessment Protocol (GAP) for antenatal detection of small for gestational age: The DESiGN cluster randomised trial. PLoS Med 2022; 19:e1004004.</a></li><li><a class="nounderline abstract_t">Rouse DJ, Owen J, Goldenberg RL, Cliver SP. Determinants of the optimal time in gestation to initiate antenatal fetal testing: a decision-analytic approach. Am J Obstet Gynecol 1995; 173:1357.</a></li><li><a class="nounderline abstract_t">Boehm FH, Salyer S, Shah DM, Vaughn WK. Improved outcome of twice weekly nonstress testing. Obstet Gynecol 1986; 67:566.</a></li><li><a class="nounderline abstract_t">Antepartum Fetal Surveillance: ACOG Practice Bulletin, Number 229. Obstet Gynecol 2021; 137:e116.</a></li><li><a class="nounderline abstract_t">Indications for Outpatient Antenatal Fetal Surveillance: ACOG Committee Opinion, Number 828. Obstet Gynecol 2021; 137:e177.</a></li><li><a class="nounderline abstract_t">Lalor JG, Fawole B, Alfirevic Z, Devane D. Biophysical profile for fetal assessment in high risk pregnancies. Cochrane Database Syst Rev 2008; :CD000038.</a></li><li><a class="nounderline abstract_t">Alfirevic Z, Stampalija T, Gyte GM. Fetal and umbilical Doppler ultrasound in high-risk pregnancies. Cochrane Database Syst Rev 2013; :CD007529.</a></li><li><a class="nounderline abstract_t">Alfirevic Z, Neilson JP. Doppler ultrasonography in high-risk pregnancies: systematic review with meta-analysis. Am J Obstet Gynecol 1995; 172:1379.</a></li><li><a class="nounderline abstract_t">Society for Maternal-Fetal Medicine Publications Committee, Berkley E, Chauhan SP, Abuhamad A. Doppler assessment of the fetus with intrauterine growth restriction. Am J Obstet Gynecol 2012; 206:300.</a></li><li><a class="nounderline abstract_t">Hutcheon JA, Lisonkova S, Magee LA, et al. Optimal timing of delivery in pregnancies with pre-existing hypertension. BJOG 2011; 118:49.</a></li><li><a class="nounderline abstract_t">Tita AT, Landon MB, Spong CY, et al. Timing of elective repeat cesarean delivery at term and neonatal outcomes. N Engl J Med 2009; 360:111.</a></li><li><a class="nounderline abstract_t">Tita ATN, Jablonski KA, Bailit JL, et al. Neonatal outcomes of elective early-term births after demonstrated fetal lung maturity. Am J Obstet Gynecol 2018; 219:296.e1.</a></li><li class="breakAll">Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy: Executive Summary https://sogc.org/wp-content/uploads/2014/05/gui307CPG1405Erev.pdf (Accessed on March 10, 2017).</li><li><a class="nounderline abstract_t">Coetzee EJ, Dommisse J, Anthony J. A randomised controlled trial of intravenous magnesium sulphate versus placebo in the management of women with severe pre-eclampsia. Br J Obstet Gynaecol 1998; 105:300.</a></li><li><a class="nounderline abstract_t">Morton A, Burke M, Jarvis E, Kumar S. Changes in proteinuria and diagnosing preeclampsia in CKD pregnancy. Pregnancy Hypertens 2020; 20:92.</a></li><li><a class="nounderline abstract_t">Samuel A, Lin C, Parviainen K, Jeyabalan A. Expectant management of preeclampsia superimposed on chronic hypertension. J Matern Fetal Neonatal Med 2011; 24:907.</a></li><li><a class="nounderline abstract_t">Vigil-De Gracia P, Lasso M, Montufar-Rueda C. Perinatal outcome in women with severe chronic hypertension during the second half of pregnancy. Int J Gynaecol Obstet 2004; 85:139.</a></li><li><a class="nounderline abstract_t">Sibai BM, Koch MA, Freire S, et al. The impact of prior preeclampsia on the risk of superimposed preeclampsia and other adverse pregnancy outcomes in patients with chronic hypertension. Am J Obstet Gynecol 2011; 204:345.e1.</a></li><li><a class="nounderline abstract_t">Bellos I, Pergialiotis V, Antsaklis A, et al. Safety of non-steroidal anti-inflammatory drugs in postpartum period in women with hypertensive disorders of pregnancy: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2020; 56:329.</a></li><li><a class="nounderline abstract_t">Pharmacologic Stepwise Multimodal Approach for Postpartum Pain Management: ACOG Clinical Consensus No. 1. Obstet Gynecol 2021; 138:507.</a></li><li><a class="nounderline abstract_t">Walters BN, Thompson ME, Lee A, de Swiet M. Blood pressure in the puerperium. Clin Sci (Lond) 1986; 71:589.</a></li><li><a class="nounderline abstract_t">Hauspurg A, Lemon LS, Quinn BA, et al. A Postpartum Remote Hypertension Monitoring Protocol Implemented at the Hospital Level. Obstet Gynecol 2019; 134:685.</a></li><li><a class="nounderline abstract_t">Glover AV, Tita A, Biggio JR, et al. Incidence and Risk Factors for Postpartum Severe Hypertension in Women with Underlying Chronic Hypertension. Am J Perinatol 2019; 36:737.</a></li><li><a class="nounderline abstract_t">Bushnell C, McCullough LD, Awad IA, et al. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45:1545.</a></li><li><a class="nounderline abstract_t">Rosenfeld EB, Brandt JS, Fields JC, et al. Chronic Hypertension and the Risk of Readmission for Postpartum Cardiovascular Complications. Obstet Gynecol 2023; 142:1431.</a></li><li><a class="nounderline abstract_t">Oben A, Szychowski JM, Ketch P, et al. Progression to Severe Chronic Hypertension 5-7 Years After a Pregnancy With Mild Chronic Hypertension. Obstet Gynecol 2022; 140:546.</a></li></ol></div><div id="topicVersionRevision">Topic 116432 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26104417" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30575676" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30681541" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : ACOG Committee Opinion No. 767 Summary: Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29133354" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29133354" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30354726" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Estimated Impact of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guidelines on Reproductive-Aged Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33787907" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prevalence of Hypertension Among Pregnant Women When Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guidelines and Association With Maternal and Fetal Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36657559" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The 2017 American College of Cardiology and American Heart Association blood pressure categories in the second half of pregnancy-a systematic review of their association with adverse pregnancy outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35482575" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hypertensive Disorders in Pregnancy and Mortality at Delivery Hospitalization - United States, 2017-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22177190" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prevalence, trends, and outcomes of chronic hypertension: a nationwide sample of delivery admissions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28697109" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pregnancy-Related Mortality in the United States, 2011-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9725924" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Risk factors for preeclampsia, abruptio placentae, and adverse neonatal outcomes among women with chronic hypertension. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11094241" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Management of mild chronic hypertension during pregnancy: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31495278" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Changes in the Prevalence of Chronic Hypertension in Pregnancy, United States, 1970 to 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28436175" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Chronic hypertension and adverse pregnancy outcome: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15207662" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Chronic hypertension and the risk for adverse pregnancy outcome after superimposed pre-eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15842204" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Maternal complications in women with chronic hypertension: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1790199" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Chronic hypertension, cigarette smoking, and abruptio placentae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24785847" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Risk of adverse pregnancy outcomes in women with mild chronic hypertension before 20 weeks of gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12151166" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Chronic hypertension in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29305253" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Chronic hypertension: first-trimester blood pressure control and likelihood of severe hypertension, preeclampsia, and small for gestational age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27620393" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The CHIPS Randomized Controlled Trial (Control of Hypertension in Pregnancy Study): Is Severe Hypertension Just an Elevated Blood Pressure?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31715148" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Chronic hypertension in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18259010" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Adverse perinatal outcomes and risk factors for preeclampsia in women with chronic hypertension: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24735917" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10214847" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Incidence of placental abruption in relation to cigarette smoking and hypertensive disorders during pregnancy: a meta-analysis of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8059820" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The prognosis of pregnancy in women with chronic hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18823491" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The association of maternal chronic hypertension with perinatal death in male and female offspring: a record linkage study of 866,188 women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21496916" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Major risk factors for stillbirth in high-income countries: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8616127" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Perinatal morbidity in chronic hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3960423" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pregnancy outcome of intensive therapy in severe hypertension in first trimester.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25951814" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Maternal Hypertension During Pregnancy and the Risk of Congenital Heart Defects in Offspring: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25265405" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Chronic hypertension in pregnancy and the risk of congenital malformations: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25395267" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Maternal hypertensive disorders, antihypertensive medication use, and the risk of birth defects: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17975258" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19061708" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28228456" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Preeclampsia and Future Cardiovascular Health: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18293207" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Systolic hypertension in pregnancy and cardiovascular mortality: a 44-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26391409" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pregnancy complications and cardiovascular disease death: 50-year follow-up of the Child Health and Development Studies pregnancy cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22169528" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Hypertensive disorders in pregnancy and risk of severe mental disorders in the offspring in adulthood: the Helsinki Birth Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23246316" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Maternal hypertensive disorders in pregnancy and self-reported cognitive impairment of the offspring 70 years later: the Helsinki Birth Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23035059" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Hypertensive disorders in pregnancy and cognitive decline in the offspring up to old age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33986467" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Clinical outcomes of hypertensive disorders in pregnancy in the offspring during perinatal period, childhood, and adolescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22010128" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17284475" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Angiotensin-converting enzyme inhibitor fetopathy: long-term outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16760444" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Major congenital malformations after first-trimester exposure to ACE inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34581729" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29138036" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36209937" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Low-dose aspirin for the prevention of superimposed preeclampsia in women with chronic hypertension: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29339829" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Associations of the dietary approaches to stop hypertension (DASH) diet with pregnancy complications in Project Viva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31717283" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Deriving the Dietary Approaches to Stop Hypertension (DASH) Score in Women from Seven Pregnancy Cohorts from the European ALPHABET Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30941817" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The efficacy of the Dietary Approaches to Stop Hypertension diet with respect to improving pregnancy outcomes in women with hypertensive disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35944931" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Replacing salt with low-sodium salt substitutes (LSSS) for cardiovascular health in adults, children and pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30575669" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : ACOG Practice Bulletin No. 203 Summary: Chronic Hypertension in Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29229741" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Accuracy of Blood Pressure Measurement Devices in Pregnancy: A Systematic Review of Validation Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30354754" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : How Do Home and Clinic Blood Pressure Readings Compare in Pregnancy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31901652" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Home blood pressure monitoring in the antenatal and postpartum period: A systematic review meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34131027" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Home blood pressure monitoring in the diagnosis and treatment of hypertension in pregnancy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29803330" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The hypertensive disorders of pregnancy: ISSHP classification, diagnosis&amp;management recommendations for international practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31501137" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Diagnosis and management of hypertension in pregnancy: summary of updated NICE guidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23900968" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Drugs for treatment of very high blood pressure during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35363951" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Treatment for Mild Chronic Hypertension during Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38078583" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2024.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35138877" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Oral Antihypertensives for Nonsevere Pregnancy Hypertension: Systematic Review, Network Meta- and Trial Sequential Analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26061848" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Less-tight versus tight control of hypertension in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25629739" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Less-tight versus tight control of hypertension in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25629739" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Less-tight versus tight control of hypertension in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27627793" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Small for Gestational Age: The Differential Mortality When Detected versus Undetected Antenatally.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18843617" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Routine ultrasound in late pregnancy (after 24 weeks' gestation).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21501426" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Screening and triage of intrauterine growth restriction (IUGR) in general population and high risk pregnancies: a systematic review with a focus on reduction of IUGR related stillbirths.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35727800" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Evaluation of the Growth Assessment Protocol (GAP) for antenatal detection of small for gestational age: The DESiGN cluster randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7503167" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Determinants of the optimal time in gestation to initiate antenatal fetal testing: a decision-analytic approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3960430" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Improved outcome of twice weekly nonstress testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34011889" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Antepartum Fetal Surveillance: ACOG Practice Bulletin, Number 229.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34011892" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Indications for Outpatient Antenatal Fetal Surveillance: ACOG Committee Opinion, Number 828.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18253968" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Biophysical profile for fetal assessment in high risk pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24222334" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Fetal and umbilical Doppler ultrasound in high-risk pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7755042" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Doppler ultrasonography in high-risk pregnancies: systematic review with meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22464066" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Doppler assessment of the fetus with intrauterine growth restriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21054760" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Optimal timing of delivery in pregnancies with pre-existing hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19129525" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Timing of elective repeat cesarean delivery at term and neonatal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29800541" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Neonatal outcomes of elective early-term births after demonstrated fetal lung maturity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29800541" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Neonatal outcomes of elective early-term births after demonstrated fetal lung maturity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9532990" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : A randomised controlled trial of intravenous magnesium sulphate versus placebo in the management of women with severe pre-eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32203727" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Changes in proteinuria and diagnosing preeclampsia in CKD pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21142774" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Expectant management of preeclampsia superimposed on chronic hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15099775" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Perinatal outcome in women with severe chronic hypertension during the second half of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21354549" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The impact of prior preeclampsia on the risk of superimposed preeclampsia and other adverse pregnancy outcomes in patients with chronic hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32068930" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Safety of non-steroidal anti-inflammatory drugs in postpartum period in women with hypertensive disorders of pregnancy: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34412076" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Pharmacologic Stepwise Multimodal Approach for Postpartum Pain Management: ACOG Clinical Consensus No. 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3769407" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Blood pressure in the puerperium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31503166" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : A Postpartum Remote Hypertension Monitoring Protocol Implemented at the Hospital Level.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30372771" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Incidence and Risk Factors for Postpartum Severe Hypertension in Women with Underlying Chronic Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24503673" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37917949" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Chronic Hypertension and the Risk of Readmission for Postpartum Cardiovascular Complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36075064" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Progression to Severe Chronic Hypertension 5-7 Years After a Pregnancy With Mild Chronic Hypertension.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
